title: Islet cell autoimmunity in type I diabetic patients after HLA-mismatched pancreas transplantation.
abstract: The aim of this study was to investigate a possible reenhancement of islet cell autoimmunity in type I (insulin-dependent) diabetic patients who received HLA-mismatched pancreas transplants from cadaveric donors and who underwent generalized immunosuppression. Circulating islet cell antibodies (ICA) and complement-fixing ICAs (CF-ICAs) have been tested at 1, 2, 3, 6, and 12 mo and at least once a year posttransplantation in 23 recipients of 25 transplants (22 simultaneous with kidney, 2 retransplants, 1 isolated; 23 segmental neoprene injected, 2 whole with enteric drainage). Patients were aged 35.3 +/- 1.9 yr with a duration of diabetes of 20.6 +/- 1.1 yr. Immunosuppression consisted of double or triple association of azathioprine, cyclosporin, and prednisone with or without temporary antilymphocyte globulins. The number of HLA-A and HLA-B compatibilities was none in 8 patients, one in 12 patients, two in 4 patients, and three in 1 patient. The mean follow-up was 4.0 +/- 0.4 yr/patient (range 0.4-7.2). ICAs were positive pretransplantation in 2 of 25 patients and reappeared 1-42 mo posttransplantation in another 7. In 6 patients, CF-ICAs were also positive. In 7 of 9 ICA+ patients the pancreas transplant failed; in 1 patient this occurred 4 mo before ICA reappearance, and in 6 patients it occurred 2-35 mo after the first detection of ICAs. Pancreas-transplant failure was significantly associated with the positivity for ICAs (P less than .05) and particularly for CF-ICAs (P less than .005). ICA positivity was transitory in 4 patients (2-27 mo) and persistent in the remaining 5 (up to 61 mo).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Medicine, San Raffaele Institute, Milan, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Bosi
authors.forename: G F
authors.initials: GF
authors.lastname: Bottazzo
authors.forename: A
authors.initials: A
authors.lastname: Secchi
authors.forename: G
authors.initials: G
authors.lastname: Pozza
authors.forename: M
authors.initials: M
authors.lastname: Shattock
authors.forename: A
authors.initials: A
authors.lastname: Saunders
authors.forename: A
authors.initials: A
authors.lastname: Gelet
authors.forename: J L
authors.initials: JL
authors.lastname: Touraine
authors.forename: J
authors.initials: J
authors.lastname: Traeger
authors.forename: J M
authors.initials: JM
authors.lastname: Dubernard
mesh_terms: D000328:Adult; D001323:Autoantibodies / Q000032:analysis*; D003168:Complement Fixation Tests; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology*; D005260:Female; D006680:HLA Antigens / Q000032:analysis*; D006650:Histocompatibility Testing; D006801:Humans; D007515:Islets of Langerhans / Q000276:immunology*; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D016035:Pancreas Transplantation
chemical_list: D001323:Autoantibodies; D006680:HLA Antigens; C024211:islet cell antibody